Placebo Response as a Signal of System Dynamics in Systemic Lupus Erythematosus Dynamic Medicine — A Clinical Trial Interpretation through the Universal Resonance Model

Fuente: Zenodo
Guardado en:
Detalles Bibliográficos
Autor principal: Domargård, Anita
Formato: Recurso digital
Lenguaje:inglés
Publicado: Zenodo 2026
Materias:
Acceso en línea:
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
_version_ 1866901265885167616
author Domargård, Anita
author_facet Domargård, Anita
contents <p>This paper examines the interpretation of placebo responses in clinical trials of systemic lupus erythematosus (SLE), using recent phase 3 data on obinutuzumab as a clinical example. While improvements observed in placebo groups are commonly attributed to nonspecific placebo effects or regression toward the mean, this analysis proposes an alternative interpretation grounded in dynamical systems thinking.</p> <p>Autoimmune diseases such as SLE may behave as dynamic biological systems characterized by fluctuations, instability, and transitions between states of higher and lower disease activity. From this perspective, part of the improvement observed in placebo groups may reflect intrinsic disease dynamics rather than purely methodological artifacts.</p> <p>The paper situates this interpretation within the framework of Dynamic Medicine and the Universal Resonance Model (URM). It is published as part of the <strong>Dynamic Medicine series</strong>, which explores how instability, timing, and system transitions shape disease behavior and clinical decision-making in complex biological systems.</p>
format Recurso digital
id zenodo_https___doi_org_10_5281_zenodo_18997018
institution Zenodo
language eng
publishDate 2026
publisher Zenodo
record_format zenodo
spellingShingle Placebo Response as a Signal of System Dynamics in Systemic Lupus Erythematosus Dynamic Medicine — A Clinical Trial Interpretation through the Universal Resonance Model
Domargård, Anita
systemic lupus erythematosus
placebo response
clinical trials
autoimmune disease dynamics
dynamical systems medicine
early-warning signals
critical transitions
system instability
Universal Resonance Model
dynamic medicine
Medicine
Immunology
Systems Biology
Systems Medicine
<p>This paper examines the interpretation of placebo responses in clinical trials of systemic lupus erythematosus (SLE), using recent phase 3 data on obinutuzumab as a clinical example. While improvements observed in placebo groups are commonly attributed to nonspecific placebo effects or regression toward the mean, this analysis proposes an alternative interpretation grounded in dynamical systems thinking.</p> <p>Autoimmune diseases such as SLE may behave as dynamic biological systems characterized by fluctuations, instability, and transitions between states of higher and lower disease activity. From this perspective, part of the improvement observed in placebo groups may reflect intrinsic disease dynamics rather than purely methodological artifacts.</p> <p>The paper situates this interpretation within the framework of Dynamic Medicine and the Universal Resonance Model (URM). It is published as part of the <strong>Dynamic Medicine series</strong>, which explores how instability, timing, and system transitions shape disease behavior and clinical decision-making in complex biological systems.</p>
title Placebo Response as a Signal of System Dynamics in Systemic Lupus Erythematosus Dynamic Medicine — A Clinical Trial Interpretation through the Universal Resonance Model
topic systemic lupus erythematosus
placebo response
clinical trials
autoimmune disease dynamics
dynamical systems medicine
early-warning signals
critical transitions
system instability
Universal Resonance Model
dynamic medicine
Medicine
Immunology
Systems Biology
Systems Medicine
url https://doi.org/10.5281/zenodo.18997018